Jason Rhodes Sells Shares of Dyne Therapeutics

Jason Rhodes, an insider at Dyne Therapeutics, Inc. (NasdaqGS: DYN), sold 147,760 shares on June 23, 2026. The shares were sold at an average price of $21.13 each, bringing the total transaction value to approximately $3.12 million. This sale was part of a pre-planned trading arrangement, often referred to as a Rule 10b5-1 plan.

Insider Buying and Selling at Dyne Therapeutics, Inc.

Several insiders at Dyne Therapeutics have been active in the market. Jason Rhodes executed multiple planned sales, including 95,900 shares at $21.02 on June 24, 2026, and 24,100 shares at $21.10 on June 25, 2026. Dirk Kersten also sold shares under a planned arrangement, with transactions on June 22 and 23, 2026, totaling over 260,000 shares. Meanwhile, Barry Greene purchased 57,463 shares on June 22, 2026, not under a planned sale.

Other Institutional Activity in Dyne Therapeutics

T. Rowe Price Investment Management significantly increased its position in Dyne Therapeutics by adding 13,245,712 shares, bringing its total to 30,785,801 shares, worth approximately $558.1 million. Janus Henderson Group reduced its stake slightly by 240,346 shares, holding 13,647,376 shares valued at about $247.4 million. BlackRock, Inc. bolstered its holdings by 509,032 shares, ending with 11,699,870 shares valued at $212.1 million. Atlas Venture Life Science Advisors maintained its position with 9,130,465 shares worth $165.5 million, while FMR LLC increased its holdings by 2,339,059 shares to a total of 8,908,980 shares, valued at $161.5 million.

Dyne Therapeutics, Inc. Stock Down 16.5%

Shares of Dyne Therapeutics traded near $20.61 on Friday. The company, with a market capitalization of $3.41 billion, operates in the biotechnology sector. Its stock has a 52-week range of $8.06 to $25.00. Dyne's financial health is reflected in its strong liquidity ratios, with a current ratio of 19.92 and a quick ratio of 18.97. The forward P/E is not meaningful due to the company's unprofitable status, with an EPS of -$3.15.

Analysts Set New Price Targets

Analysts have been active in covering Dyne Therapeutics. On May 15, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $33. Bernstein kept a 'hold' rating with a $24 target on May 13, 2026. Chardan Capital reiterated its 'buy' rating, setting a target of $38 on March 9, 2026, and HC Wainwright & Co. also maintained a 'buy' with a $50 target on March 3, 2026. The consensus among 16 analysts is a 'strong buy', with an average price target of $38.25.

About Dyne Therapeutics

Dyne Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapies for neuromuscular diseases, using its proprietary FORCE platform to deliver treatments for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and other muscle-related diseases. The company, led by CEO John G. Cox, employs 263 people and is dedicated to advancing clinical-stage solutions for rare muscle diseases.

Bottom Line

The recent insider selling activity by Jason Rhodes at Dyne Therapeutics is noteworthy, especially as it was part of a planned trading arrangement. Investors often monitor such insider transactions for potential insights into the company's future prospects. However, it's important to remember that insider sales can occur for various personal reasons and don't necessarily reflect the company's performance outlook. Dyne's stock remains a focus for institutional investors and analysts, highlighting its potential in the biotechnology sector.